Modality
Bispecific Ab
MOA
KRASG12Ci
Target
KRASG12D
Pathway
Tau
Hemophilia ACF
Development Pipeline
Preclinical
~Sep 2013
→ ~Dec 2014
Phase 1
~Mar 2015
→ ~Jun 2016
Phase 2
~Sep 2016
→ ~Dec 2017
Phase 3
Mar 2018
→ Oct 2031
Phase 3Current
NCT04980237
2,447 pts·CF
2018-03→2031-10·Not yet recruiting
NCT08530281
803 pts·Hemophilia A
2025-05→2029-07·Active
3,250 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-07-143.3y awayPh3 Readout· Hemophilia A
2031-10-075.5y awayPh3 Readout· CF
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Not yet…
P3
Active
Catalysts
Ph3 Readout
2029-07-14 · 3.3y away
Hemophilia A
Ph3 Readout
2031-10-07 · 5.5y away
CF
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04980237 | Phase 3 | CF | Not yet recr... | 2447 | Mayo |
| NCT08530281 | Phase 3 | Hemophilia A | Active | 803 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D |